Prescient Healthcare Group Strengthens Its US Leadership Team
Prescient Healthcare Group Strengthens Its US Leadership Team
Prescient appoints Dr. Paul Harney as President, North America
LONDON, July 17, 2018—Prescient Healthcare Group, a biopharmaceutical product and portfolio strategy firm, announces the recent appointment of Dr. Paul Harney as President, North America. He has also been named to Prescient’s Board of Directors.
Paul joins Prescient after spending more than 20 years providing guidance and support to the healthcare industry. Since completing his PhD in chemistry at Stony Brook University, Paul has held leadership roles at various firms including Deloitte Consulting, Quintiles and IQVIA. His areas of expertise include marketing, sales force optimization, medical affairs, business development and supply chain. At Prescient, Paul is responsible for enhancing and delivering the company’s US growth strategy while also ensuring high levels of client satisfaction.
“What Prescient has built really excites me and I see a huge potential to scale the US business. Our rich scientific, clinical and analytics heritage means we are perfectly positioned to help clients bring products with strong clinical benefits and attractive value propositions to market,” Harney said. “I’ve inherited an impressive team and look forward to continuing to enhance the depth and breadth of services we bring to our clients.”
Dr. Mark Little, the former President, North America, will remain with Prescient as a Senior Vice President. He will devote more time to developing client relationships, leading client engagements and expanding the development of Prescient’s thought leadership presence.
“Paul brings a rare balance of corporate best practice, a values-based leadership style and the pragmatism required to scale and develop a small and fast-growing consultancy,” said Jamie Denison-Pender, Prescient’s CEO. “His combination of consultancy, outsourcing and advertising experience means he has a highly nuanced understanding of the opportunities and challenges facing our clients.”
“We also wish to thank Mark for his five years of exceptional leadership, which has seen the US business more than double in size. He has built a fantastic reputation both internally and within the market. Paul, the broader team and I are delighted that we will continue to benefit from his wisdom and guidance,” said Denison-Pender.
Biographies and contact information for Dr. Harney and Dr. Little can be found on: www.PrescientHG.com.
About Prescient
Prescient Healthcare Group is a biopharmaceutical product and portfolio strategy firm that helps clients develop, launch and market medicines that expand treatment options, optimize patient outcomes and deliver high levels of return. From offices in London, New York, San Francisco, New Delhi and Beijing, Prescient supports the development of strategy for many of the most exciting assets and brands.
Prescient has been a portfolio company of Baird Capital since 2017.
For more information, please visit www.PrescientHG.com.
Contact:
Christina Maffei
+1 908 342 3556
cmaffei@prescienthg.com
